Klin Onkol. 2023 Spring;36(2):135-142. doi: 10.48095/ccko2023135.
Head-and-neck malignant neoplasms (diagnosis group C00-C14, according to ICD-10) form a heterogeneous group of diseases with close anatomical localization. The incidence is twice to three times higher in men than in women and is increasing worldwide.
The aim of our analysis was to estimate changes of incidence and mortality rates of head-and-neck malignancies associated with anatomical topographic regions over the time as well as to compare these indicators in different selected countries of the world. Secondary endpoints included the assessment of patients' age distribution, clinical stages of newly diagnosed cases, and point prevalence of the disease in the Slovak Republic (SR).
The data base for the calculations was obtained from national databases and outputs of the National Cancer Registry (NCR) of the SR (with summary data available from the National Epidemiological Portal of Malignant Tumors, which analyzed data from 1984-2003 and was available until 2009, the remaining data were obtained from annual analyses of the NCR of the SR and the National Centre for Health Information (NCZI)), from the Statistical Office of the SR, and from the IARC WHO global database outputs on incidence, mortality, prevalence and survival of the patients. Incidence and mortality data in the SR were available up to 2012 (including) and up to 2021 (including), respectively. A log-linear joinpoint regression model was used to analyze the development of incidence and mortality rates over time by using Joinpoint Regression Program software. To achieve maximum precision in the estimated total surviving population of patients with head and neck malignant neoplasms, a model was developed to calculate the point (overall) prevalence based on absolute numbers of long-term registered national counts of newly diagnosed patients, mortality from the disease, overall mortality, and survival probability. The representation of clinical stages of head and neck carcinoma in the SR was compiled from available national data (2000-2012) and from predictions and does not consider changes in TNM classifications over the time.
The age-adjusted (to the world standard population, ASR-W) incidence rate and the age-adjusted (ASR-W) mortality rate of head-and-neck malignant tumors in the SR have shown a significantly decreasing tendency in men since 1990; however, in women both of these indicators have shown a significant increasing tendency, especially the significantly growing incidence since 2004. In 2012, the overall age-adjusted incidence and mortality rate of head-and-neck cancers in the SR were significantly higher in males (ASR-W incidence 22.6/100,000 and ASR-W mortality 15.26/100,000) compared to females (ASR-W incidence 4.21/100,000 and ASR-W mortality 1.52/100,000). More than 75% of newly diagnosed cases are already in advanced and metastatic clinical stages, which is the most unfavourable survival factor. The absolute prevalence of these patients in the SR was estimated to be N = 9,395 in the year 2021.
It is necessary to get a current and well evaluated epidemiological overviews to be able to plan preventive and intervention programs in oncology.
头颈部恶性肿瘤(根据 ICD-10 分类为 C00-C14)构成一组具有密切解剖定位的异质性疾病。其发病率男性是女性的两倍至三倍,且在全球范围内呈上升趋势。
我们分析的目的是评估与解剖区域相关的头颈部恶性肿瘤的发病率和死亡率随时间的变化,并比较世界上不同选定国家的这些指标。次要终点包括评估患者的年龄分布、新诊断病例的临床分期以及斯洛伐克共和国(SR)的疾病时点患病率。
计算所使用的数据来自国家数据库和 SR 国家癌症登记处(NCR)的输出(从国家恶性肿瘤流行病学门户网站获得汇总数据,该门户网站分析了 1984-2003 年的数据,并于 2009 年之前可用,其余数据来自 SR NCR 的年度分析和国家卫生信息中心(NCZI))、来自 SR 统计局以及国际癌症研究机构(IARC)WHO 全球数据库关于患者发病率、死亡率、患病率和生存率的输出。SR 中的发病率和死亡率数据分别截至 2012 年(含)和 2021 年(含)。使用 Joinpoint Regression Program 软件通过对数线性连接点回归模型分析发病率和死亡率随时间的变化。为了在估计头颈部恶性肿瘤患者的总存活人数方面达到最大精度,开发了一种基于新诊断患者的国家长期登记人数、疾病死亡率、总死亡率和生存率的绝对数值来计算时点(总体)患病率的模型。SR 中头颈部癌的临床分期代表来自可用的国家数据(2000-2012 年)和预测,不考虑随着时间的推移 TNM 分类的变化。
自 1990 年以来,SR 中男性头颈部恶性肿瘤的年龄调整(与世界标准人口相比,ASR-W)发病率和年龄调整(ASR-W)死亡率呈显著下降趋势;然而,在女性中,这两个指标均呈显著上升趋势,尤其是 2004 年以来发病率显著增长。2012 年,SR 中头颈部癌症的总体年龄调整发病率和死亡率在男性中显著高于女性(ASR-W 发病率 22.6/100,000,ASR-W 死亡率 15.26/100,000)与女性(ASR-W 发病率 4.21/100,000,ASR-W 死亡率 1.52/100,000)。超过 75%的新诊断病例已经处于晚期和转移性临床阶段,这是最不利的生存因素。据估计,2021 年 SR 中这些患者的绝对患病率为 N = 9,395。
为了能够规划肿瘤学中的预防和干预计划,有必要获得当前和经过良好评估的流行病学概述。